Navigation Links
The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
Date:8/19/2007

Phase 2 Study to Explore the Efficacy of Novel Proteasome Inhibitor in

Patients with Relapsed and Refractory Multiple Myeloma

SOUTH SAN FRANCISCO, Calif. and NORWALK, Conn., Aug. 15 /PRNewswire/ -- The Multiple Myeloma Research Consortium (MMRC) and Proteolix, Inc. today announced the enrollment of the first patient in a multi-center Phase 2 clinical trial to study Proteolix's potent and selective proteasome inhibitor, carfilzomib (PR-171), in patients with relapsed and refractory multiple myeloma. Ten MMRC Member Institutions will participate in the study, under the MMRC leadership of Melissa Alsina, MD, H. Lee Moffitt Cancer Center & Research Institute. The nine additional sites are the City of Hope, Emory University, Cancer Center at Hackensack University Medical Center, Mayo Clinic, Princess Margaret/University Health Network, Saint Vincent's Comprehensive Cancer Center, University of Michigan, and Washington University.

The MMRC is the only research model of its kind that brings together 13 leading academic institutions to accelerate the development of novel and combination treatments for multiple myeloma, an incurable cancer of the plasma cell.

"Proteasome inhibitors are an important class of drugs for the treatment of multiple myeloma and we are proud to work with Proteolix to advance the clinical development of carfilzomib," said Kathy Giusti, Founder and Chief Executive Officer of the MMRC. "This trial and the others the MMRC are facilitating underscore our commitment to bring better, more effective treatments to myeloma patients as quickly as possible."

The trial will evaluate the overall response rate (ORR) for two cycles of carfilzomib in patients with multiple myeloma who have previously received specific FDA-approved therapies, have relapsed after two or more of such therapies, and are refractory to the most recently received therapy. Secondary objectives of this study include safety and tolerability, clinica
'/>"/>

SOURCE Proteolix

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
2. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
3. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
4. Gentiums Defibrotide Seen as Active in Multiple Myeloma
5. ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model
6. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
7. CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
9. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
10. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
11. Orchestra Therapeutics Announces New Phase II Clinical Data on NeuroVax Demonstrating Marked Expansion of Regulatory T Cell Populations in Patients With Multiple Sclerosis

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...ov. 20 Smith & Nephe... to announce the signing of a technology developme...efense that may lead to the creation of a fracture...atment of the limbs of soldiers who sustain battle...ced Research Projects Agency (DARPA), the central ...
(Date:11/19/2009)... Nov. 19 In a series of ...ce, Heska Corporation (Nasdaq: HSKA ) ("Heska" or...new and improved website. The upgraded site is th... programming to align the site with the company,s ...Logo: http://www.newscom.com/cgi-bin/prnh/200006...
(Date:11/19/2009)..., Nov. 19 Ligon Discovery, Inc., w...chnology to find drugs against high-value targets,...nancing led by incTANK Ventures. The company will ...campaign that will screen over 100 high-value dise... Ventures General Partner Christian Bailey joins t...
Breaking Medicine Technology:Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 2Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 3Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 4Heska Announces Launch of New Website 2Heska Announces Launch of New Website 3Cambridge-based Ligon Discovery Raises $1M in Seed Funding 2Cambridge-based Ligon Discovery Raises $1M in Seed Funding 3Heart Drug Combos Raise Risk of Gastrointestinal Bleeding 47680 1Heart Drug Combos Raise Risk of Gastrointestinal Bleeding 47680 2Halogen Delivers Talent Management Industry 26apos 3Bs Most Comprehensive Value Add Content for Healthcare Customers 47676 1Halogen Delivers Talent Management Industry 26apos 3Bs Most Comprehensive Value Add Content for Healthcare Customers 47676 2Halogen Delivers Talent Management Industry 26apos 3Bs Most Comprehensive Value Add Content for Healthcare Customers 47676 3Halogen Delivers Talent Management Industry 26apos 3Bs Most Comprehensive Value Add Content for Healthcare Customers 47676 4When evolution is not so slow and gradual 8702 1When evolution is not so slow and gradual 8702 2
...on,s Immunization Project aims to, raise awarene...on, and increase vaccine complia.../-- The COSHAR Foundation, a,nonprofit organizatio...mpowerment with a focus on minority and disadvanta...ion awareness campaign, Protecting our Future:,The...
...23 ,Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX ),...ery and development of drugs for the treatment of,...nnounced preclinical data,from the company,s polym...tment of hepatitis C. These data are being present...on for the Study of the Liver (EASL) being,held th...
Other Medicine Technology:The COSHAR Foundation Launches National Childhood Immunization Awareness Campaign During National Infant Immunization Week (April 19-26) 2The COSHAR Foundation Launches National Childhood Immunization Awareness Campaign During National Infant Immunization Week (April 19-26) 3Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL) 2Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL) 3Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL) 4
(Date:11/20/2009)...ov. 20 Centene Corpora...resent at the Bank of America Merrill Lynch 2009 C...t the Crowne Plaza Hotel Times Square in New York ...er 2nd at 8:30 a.m. Eastern Time. Investors and ot...bcast of Centene,s presentation at: http://www.ve...
(Date:11/20/2009)...Nov. 20 SIRIUS XM Radio...oadcast Doctor Radio Reports: What Every Women ...al hosted by veteran journalist Perri Peltz. ,...0819/NYTU044LOGO ) ,, Doctor Radio Reports: ...ill air November 21 live at 10:00 am ET on Docto...
(Date:11/20/2009)...vember 20, 2009Emergency medical service (EMS) pro...0,000 cardiac arrests each year. Only 5 to 10 per...ive. Better quality cardiopulmonary resuscitation...e associated with better patient outcome. The Res...t clinical research network to study prehospital t...
(Date:11/20/2009)...severe cases than with seasonal flu , ,...archers are reporting that children with asthma ar...than seasonal flu. , "Asthma has been identifie...pandemic H1N1 influenza, present in 21 percent to ... Allen and fellow researchers from the Hospital fo...
(Date:11/20/2009)...., Nov. 20 Missouri state employee...ons will now have the option to choose Mercy Healt...ween Missouri Consolidated Health Care Plan (MCHCP...South Central Missouri regions include the followi..., Dallas, Douglas, Greene, Hickory, Howell, Jasper...
Breaking Medicine News(10 mins):Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: What Every Woman Needs To Know About Mammograms' 2Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: What Every Woman Needs To Know About Mammograms' 3Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: What Every Woman Needs To Know About Mammograms' 4Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: What Every Woman Needs To Know About Mammograms' 5Health News:Effect of real-time CPR feedback reported at resuscitation science symposium 2Health News:Effect of real-time CPR feedback reported at resuscitation science symposium 3Health News:Missouri Consolidated Health Care Plan Provides Mercy Health Plans Option 2
...and West Penn Allegheny,Health System (WPAHS) anno...number of new initiatives and senior-directed prog...ies have improved access and choice in their,healt...ns best-known medical facilities including two ter...
...nates Annual Audits & Contentious Audit ... MILWAUKEE, Dec. 5 InvoiceCHECK, an innovative fo...y PBM claims billings for each,invoice, has been i...ion benefit,claims., "Every time that an employer...
...rdia, Inc., a,medical device company developing en...onic total occlusion (CTO) recanalization, today a...o the position of Senior Vice,President, Sales. Mr...ts field., Most recently, Mr. Barys served as Vic...
... Adding Dental to Medical Benefits, HOUSTON, Dec....rovider that offers uninsured or partially insured... on healthcare, today announced the,formation of i...,000 dentist access points serving over 4.5 millio...
...dings, Inc.,(OTC Bulletin Board: NEXA), a diversif...tail, health & beauty, and real estate, issued the... Richard Surber., Dear Valued Shareholders:, I a...it to be effective by December 14, 2007. I,also ex...
...m Medical,Inc. (Nasdaq: BFRM ) announced that on ...ptember 30, 2007 first quarter fiscal year 2008 fi...gs press release after the NASDAQ,Global Market cl...and Chief Financial Officer,Derek Bertocci will di...
Other Medicine News:Health News:Bravo Health and West Penn Allegheny Health System Partner to Offer Seniors Improved Access and Choice in Healthcare 2Health News:'InvoiceCHECK' Cuts Prescription Benefit Waste 2Health News:FlowCardia, Inc. Appoints Chris Barys Senior VP, Sales 2Health News:DenteMax Forms Business Alliance With MEDILINQ 2Health News:Nexia Holdings CEO Issues Update to Shareholders 2Health News:Nexia Holdings CEO Issues Update to Shareholders 3Health News:Nexia Holdings CEO Issues Update to Shareholders 4Health News:BioForm to Announce First Quarter Fiscal 2008 Financial Results and Host Conference Call and Webcast on December 13, 2007 2
Complete brand Blink-N-Clean Lens Drops
Renu Rewetting Drops
Softwear Saline
Sensitive Eyes Sterile Saline Spray
Medicine Products: